The pharmaceutical industry has immense pressure to deliver advanced and novel therapies to patients worldwide but faces monumental challenges in drug development. On average, the journey from discovery of a compound to a marketed product spans over a ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Deal announcements often showcase where the stars align in pharma around up-and-coming therapeutic areas, companies ...

Jessica Calef, head of OTC and pharma partnerships at Reddit, will provide the morning keynote at the 2025 MM+M Media Summit.

Pharmaceutical drug discovery and development have grown increasingly difficult over the years. Yes, there have been great breakthroughs in technology that can facilitate research processes and the explosion of science in understanding the causes of ...

Iris brings over 30 years of global leadership in clinical development, regulatory strategy, and pharmaceutical R&D execution. From 2008 to 2024, she served as Executive Vice President, Chief Medical Officer, and Head of Development at UCB, where she led ...

Research and development (R&D) spending by drug manufacturers flatlined in 2022, according to data released by Evaluate Vantage Friday morning. Among the world’s largest 11 drugmakers, only AstraZeneca and Sanofi showed any “real uptick” in R&D ...

The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays (D-MNA) representing ~$2 billion in potential market opportunity The Company plans to complete patient recruitment for SKNJCT-003 before the end of Q4 2025 and to request End-of-Phase 2 (EOP2)

Pharmacists deliver life-changing healthcare. Their compassionate guidance educates patients on how to make the safest and best use of their prescribed medications. The University of Wyoming School of Pharmacy offers a four-year program leading to the ...

Domestic pharmaceutical companies are intensifying efforts to develop new forms of obesity treatments, challenging the market dominated by Danish company Novo Nordisk’s “Wegovy” and U.S. firm Eli Lilly’s “Mounjaro.

The move affects 71 diploma in pharmacy (D. Pharma) and 18 bachelor of pharmacy (B. Pharm) institutions in the state, according to documents reviewed by Mint and people familiar with matter.